Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | A2B395 |
Synonyms | |
Therapy Description |
Limited information is currently available on A2B395, a putative chimeric antigen receptor (CAR) T-cell therapy targeting EGFR (Nov 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
A2B395 | A-2B395|A 2B395 | Limited information is currently available on A2B395, a putative chimeric antigen receptor (CAR) T-cell therapy targeting EGFR (Nov 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06682793 | Phase Ib/II | A2B395 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression (DENALI-1) | Not yet recruiting | USA | 0 |